These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3238650)

  • 1. Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys.
    Erdjument H; Lane DA; Ireland H; Di Marzo V; Panico M; Morris HR; Tripodi A; Mannucci PM
    Thromb Haemost; 1988 Dec; 60(3):471-5. PubMed ID: 3238650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombin Sheffield: amino acid substitution at the reactive site (Arg393 to His) causing thrombosis.
    Lane DA; Erdjument H; Flynn A; Di Marzo V; Panico M; Morris HR; Greaves M; Dolan G; Preston FE
    Br J Haematol; 1989 Jan; 71(1):91-6. PubMed ID: 2917133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow.
    Erdjument H; Lane DA; Panico M; Di Marzo V; Morris HR
    J Biol Chem; 1988 Apr; 263(12):5589-93. PubMed ID: 3162733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin Chicago, amino acid substitution of arginine 393 to histidine.
    Erdjument H; Lane DA; Panico M; Di Marzo V; Morris HR; Bauer K; Rosenberg RD
    Thromb Res; 1989 Jun; 54(6):613-9. PubMed ID: 2781509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel amino acid substitution in the reactive site of a congenital variant antithrombin. Antithrombin pescara, ARG393 to pro, caused by a CGT to CCT mutation.
    Lane DA; Erdjument H; Thompson E; Panico M; Di Marzo V; Morris HR; Leone G; De Stefano V; Thein SL
    J Biol Chem; 1989 Jun; 264(17):10200-4. PubMed ID: 2722864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation of a covalent disulfide-linked antithrombin-albumin complex by an antithrombin variant, antithrombin "Northwick Park".
    Erdjument H; Lane DA; Ireland H; Panico M; Di Marzo V; Blench I; Morris HR
    J Biol Chem; 1987 Oct; 262(28):13381-4. PubMed ID: 3654616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification and further characterization of antithrombin III Milano: lack of reactivity with thrombin.
    Wolf M; Boyer-Neumann C; Meyer D; Tripodi A; Mannucci PM; Larrieu MJ
    Thromb Haemost; 1987 Oct; 58(3):888-92. PubMed ID: 3433251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microheterogeneity of antithrombin III: effect of single amino acid substitutions and relationship with functional abnormalities.
    De Stefano V; Leone G; Mastrangelo S; Lane DA; Girolami A; de Moerloose P; Sas G; Abildgaard U; Blajchman M; Rodeghiero F
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):7-15. PubMed ID: 8180341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin.
    Lane DA; Flynn A; Ireland H; Erdjument H; Samson D; Howarth D; Thompson E
    Br J Haematol; 1987 Apr; 65(4):451-6. PubMed ID: 3580302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa.
    Austin RC; Rachubinski RA; Ofosu FA; Blajchman MA
    Blood; 1991 May; 77(10):2185-9. PubMed ID: 2029579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.
    Borg JY; Owen MC; Soria C; Soria J; Caen J; Carrell RW
    J Clin Invest; 1988 Apr; 81(4):1292-6. PubMed ID: 3350974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin III "Northwick Park": a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity.
    Howarth DJ; Samson D; Stirling Y; Seghatchian MJ
    Thromb Haemost; 1985 Jun; 53(3):314-9. PubMed ID: 4049307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A; Krachmalnicoff A; Mannucci PM
    Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombin Milano: a new variant with monomeric and dimeric inactive antithrombin III.
    Wolf M; Boyer C; Tripodi A; Meyer D; Larrieu MJ; Mannucci PM
    Blood; 1985 Feb; 65(2):496-500. PubMed ID: 3967090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate.
    Caso R; Lane DA; Thompson EA; Olds RJ; Thein SL; Panico M; Blench I; Morris HR; Freyssinet JM; Aiach M
    Br J Haematol; 1991 Jan; 77(1):87-92. PubMed ID: 1998601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin.
    Ireland H; Lane DA; Thompson E; Walker ID; Blench I; Morris HR; Freyssinet JM; Grunebaum L; Olds R; Thein SL
    Br J Haematol; 1991 Sep; 79(1):70-4. PubMed ID: 1911389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites.
    Desai UR; Petitou M; Björk I; Olson ST
    Biochemistry; 1998 Sep; 37(37):13033-41. PubMed ID: 9737884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity.
    Olson ST; Frances-Chmura AM; Swanson R; Björk I; Zettlmeissl G
    Arch Biochem Biophys; 1997 May; 341(2):212-21. PubMed ID: 9169007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid identification of specific mutations in the sequence of an enzyme variant produced by protein engineering using high-performance liquid chromatographic/fast atom bombardment mass spectrometric techniques.
    van Dongen WD; van Bommel JH; van Wassenaar PD; Heerma W; Haverkamp J
    Biol Mass Spectrom; 1994 Nov; 23(11):675-81. PubMed ID: 7811756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.